RCT: Safety and efficacy of AGN-190584 in individuals with presbyopia.
22 Mar, 2022 | 08:20h | UTC
Commentary on Twitter
A new proprietary formulation of pilocarpine developed to treat presbyopia met its primary endpoint in the GEMINI phase 3 clinical trial, safely and effectively improving distance-corrected mesopic near vision for hours after eye drop instillation. https://t.co/WG5DZ6XQxZ pic.twitter.com/YXnW387R7i
— JAMAOphthalmology (@JAMAOphth) March 4, 2022